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Introduction: The purpose of this study was to investigate the con-
tinuous changes in three distinct response assessment methods 
during treatment as a marker of response for patients with meso-
thelioma. Linear tumor thickness measurements, disease volume 
 measurements, and lung volume measurements (a physiological 
 correlate of disease volumes) were investigated in this study.
Methods: Serial computed tomography scans were obtained  during 
the course of clinically standard chemotherapy for 61 patients. 
For each of the 216 computed tomography scans, the aerated lung 
 volumes were segmented using a fully automated method, and the 
pleural disease volume was segmented using a semiautomated 
method. Modified Response Evaluation Criteria in Solid Tumors 
 linear-thickness measurements were acquired clinically. Diseased 
(ipsilateral) lung volumes were normalized by the respective con-
tralateral lung volumes to account for the differences in inspiration 
between scans for each patient. Relative changes in each metric from 
baseline were tracked over the course of follow-up imaging. Survival 
modeling was performed using Cox proportional hazards models 
with time-varying covariates.
Results: Median survival from pretreatment baseline imaging was 
12.7 months. A negative correlation was observed between measure-
ments of lung volume and disease volume, and a positive correlation 
was observed between linear-thickness measurements and disease 
volume. As continuous numerical parameters, all three response 
assessment methods were significant imaging biomarkers of patient 
prognosis in independent survival models.
Conclusions: Analysis of trajectories of linear-thickness measure-
ments, disease volume measurements, and lung volume measure-
ments during chemotherapy for patients with mesothelioma indicates 
that increasing linear thickness, increasing disease volume, and 
decreasing lung volume are all significantly and independently asso-
ciated with poor patient prognosis.
Key Words: Chest CT, Malignant pleural mesothelioma, Therapy 
response assessment.
(J Thorac Oncol. 2013;8: 478-486)
For matters involving tumor response, there is only one met-ric that can be used to ascertain the truth: tumor burden. If 
tumor composition is assumed to be consistent over time, then 
changes in tumor volume will directly correspond to changes 
in the number of tumor cells. Some molecular imaging meth-
ods are moving toward proliferative cellular quantification.1–3 
However, until these methods become widespread, computed 
tomography (CT) imaging (with the possibility of volumetric 
quantification) will remain the best tool to assess the tumor bur-
den for patients with malignant pleural mesothelioma (MPM).
Advances in medical imaging and image processing 
methodology allow for response assessment metrics that 
(1) use full three-dimensional volume measurements4–6 and 
(2) track continuous, rather than discretized, measurements 
over time.7,8 Disease volumes are a logical choice for tumor 
burden assessment of diseases such as mesothelioma, where 
the disease morphology is not compatible with the spherical 
geometry assumptions implicit in the Response Evaluation 
Criteria In Solid Tumors (RECIST) response assessment 
technique.9–11 The segmentation and volumetric quantifica-
tion of mesothelioma with any degree of automation is a 
challenging task. The morphology of the disease is widely 
variable, and its radiographic density is comparable to that 
of neighboring tissues.12 Although volume measurements of 
MPM have been shown to exhibit lower interobserver vari-
ability than linear-thickness measurements made according 
to the modified RECIST protocol,13,14 the computational and 
manual challenges of the disease volume segmentation task 
are problematic.
Pleural disease volume was previously shown to be a 
significant predictor of MPM patient survival,3,15,16 but changing 
tumor burden affects more than just the volume of tumor. The 
hemithoracic space is fairly fixed so that when disease volume 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0804-0478
Lung Volume Measurements as a Surrogate Marker for 
Patient Response in Malignant Pleural Mesothelioma
Zacariah E. Labby, PhD,* Samuel G. Armato, III, PhD,* James J. Dignam, PhD,†  
Christopher Straus, MD,* Hedy L. Kindler, MD,‡ and Anna K. Nowak, MD, PhD§ǁ
*Department of Radiology, The University of Chicago, Chicago, IL; 
†Department of Health Studies, The University of Chicago, Chicago, 
IL; ‡Department of Medicine, The University of Chicago, Chicago, 
IL; §Department of Medical Oncology, Sir Charles Gairdner Hospital, 
Nedlands, Western Australia, Australia; and ǁSchool of Medicine and 
Pharmacology, University of Western Australia, Crawley, Western Australia, 
Australia.
Address for correspondence: Samuel G. Armato III, PhD, Department of 
Radiology, The University of Chicago, 5841 S Maryland Ave., MC 2026, 
P-104, Chicago, IL 60637. E-mail: s-armato@uchicago.edu
Disclosure: Dr. Armato receives royalties and licensing fees through the 
University of Chicago related to computer-aided diagnosis.
This work was supported by The University of Chicago Comprehensive 
Cancer Center; the Raine Medical Research Foundation; the US National 
Institutes of Health (grant numbers T32EB002103, R01CA102085); the 
Simmons Mesothelioma Foundation; the Kazan Law Firm’s Charitable 
Foundation; the National Health and Medical Research Council, Australia; 
and the Cancer Council Western Australia.
ORIGINAL ARTICLE
479Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013 Lung Volume Measurements as a Marker of Response
increases, aerated lung volume should be expected to decrease 
correspondingly. This physiologic correlation implies that 
changes in lung volume may have prognostic value for patients 
with MPM. Lung volume has been investigated to monitor 
response to surgical MPM tumor debulking17; changes in lung 
volume may also be a useful tool to assess tumor response for 
patients receiving chemotherapy so that instead of classifying 
response from declining tumor volume, response would be 
classified from increasing lung volume.
Both the linear measurements based on modified 
RECIST15 and lung volumes have certain advantages over 
disease volumes for response assessment. Disease volumes 
require substantial manual intervention. Linear-thickness 
measurements are almost entirely manual (though some auto-
mation techniques have been suggested)18 but require much 
less time than disease volume segmentation. Lung volume 
segmentation, on the other hand, is entirely automated. The 
purpose of this study was to compare the prognostic per-
formance of changing lung volumes and linear-thickness 
measurements (treated continuously) with changing disease 
volumes in survival models for patients with MPM.
PATIENTS AND METHODS
Patient Cohort
Imaging and clinical data from 61 patients were 
obtained from a prospective study involving FDG-positron 
emission tomography and CT imaging of MPM.3 All patients 
were older than 18 years with histologically or cytologically 
confirmed MPM and had not received previous chemotherapy 
or definitive radiotherapy. Patient accrual occurred from late 
2003 to 2010, and the original study was approved by the 
local institutional Human Research Ethics Committee at Sir 
Charles Gairdner Hospital (Nedlands, Australia) with patients 
providing written informed consent. The retrospective analysis 
of the Health Insurance Portability and Accountability Act-
compliant data was approved by both the originating institu-
tion’s Human Research Ethics Committee and the Institutional 
Review Board at The University of Chicago, where the analy-
sis was performed. Because the original study did not mandate 
a specific treatment protocol, patients were treated as clinically 
indicated. Initially, combination chemotherapy consisted of 
cisplatin and gemcitabine and later, when it became available 
at the original study institution, cisplatin and pemetrexed. For 
inclusion in this study, patients were required to have available 
modified RECIST tumor thickness measurements at baseline 
(before beginning the chemotherapy) and one or more follow-
up scans during chemotherapy. As lung volume analysis was 
limited to patients with one nondiseased lung to serve as a con-
trol, the patients were also required to have unilateral disease. 
Finally, all patients were required to have a complete thoracic 
CT scan for all scan dates (and not simply scanned films) for 
automated lung segmentation. The summary description of the 
patient cohort is given in Table 1.
Imaging
Patients were imaged using helical CT up to 1 month 
before the first cycle of chemotherapy and throughout their 
treatment regimen (typically after the first cycle, then every 
two cycles thereafter). CT staging was performed according 
to the Union for International Cancer Control TNM staging 
system (2002). CT scans were staged by a thoracic radiologist 
or medical oncologist experienced in mesothelioma imaging, 
and tumor measurements were made clinically according to 
the modified RECIST protocol on baseline and all follow-up 
scans.13 Pathologic staging was not performed. The clinical 
measurement protocol dictated that all imaging examinations 
from an individual patient be measured by the same clinician 
in an attempt to minimize variability.
A total of 216 CT scans were used in this study, with 
a median of four scans per patient. Eight patients had only 
a baseline scan with one follow-up scan, while 19 patients 
had three scans in total, 27 patients had four scans in total, 
and seven patients had five scans in total. The median inter-
val between scans was 48 days. Of the 216 scans, 150 scans 
had been performed on General Electric scanners (HiSpeed 
CT/i, n  = 81; LightSpeed Pro 16, n  = 1; or LightSpeed VCT, 
n  = 68; General Electric Co., Waukesha, WI), and 66 scans 
had been performed on Philips Brilliance 64-slice scanners 
(Philips Medical Systems, Cleveland, OH). At least 101 of the 
scans were performed with iodinated contrast media.
Only one reconstructed series was required for lung and 
disease segmentation for each CT scan date, and this series 
was selected for each patient with consideration for recon-
struction kernel and slice thickness. Preference was given 
to thinner slice thicknesses and “standard” reconstruction 
kernels, but if for a given patient, there was a scan date with 
only “lung” kernel reconstructions, then matched kernel and 
slice thickness reconstructions were used for the other scan 
dates. Having this type of consistency across the scan dates 
for a given patient was considered important for segmentation 
of volumetric disease, because different amounts of disease 
might be segmented on different reconstructions due to, for 
instance, partial volume effects. Although linear-thickness 
measurements were consistently acquired using 5-mm recon-
structions, multiple reconstructed slice thicknesses existed 
for each CT scan. For the series used in the lung and disease 
segmentation components of this study, slice thicknesses were 
0.63 mm (n = 4), 1 mm (n = 14), 1.25 mm (n = 28), 2.5 mm (n = 
75), or 5 mm (n = 95). In-plane voxel dimensions ranged from 
0.54 to 0.86 mm, and all reconstructed axial images had an in-
plane matrix size of 512 by 512 pixels. The kVp setting for the 
scans was predominantly 120 kVp (n = 212), with 100 kVp 
(n = 1) and 140 kVp (n = 3) also used. Reconstruction kernels 
fell into two broad categories, with “Lung” kernels (including 
the Philips “L” and General Electric “Lung” kernels) used for 
136 scans and “Standard” kernels (including Philips “B” and 
General Electric “chest,” “soft,” and “standard” kernels) used 
for the remaining 80 scans.
Lung and Disease Volume Quantification
Lung region segmentation was performed using a 
segmentation algorithm described previously by Sensakovic 
et al.19 The lung segmentation method is fully automated and 
utilizes gray-level, morphological, and texture features to 
segment the aerated lung regions. The lung segmentation method 
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has proven successful in other studies for patients with MPM.17,20 
The resulting segmentations were all reviewed for accuracy 
and modified when necessary by an observer (Z.E.L.) trained 
in thoracic anatomy. In-house software was used for this task 
(Abras), and duration of any necessary intervention was tracked.
The pleural disease was segmented in each scan using a 
semiautomated method described previously.21 Because of the 
considerable overlap in Hounsfield Unit values between meso-
thelioma tumor and pleural effusion,12 the semiautomated 
disease volume segmentation method produces contours 
of pleural disease and does not readily separate tumor from 
effusion. Therefore, the end goal of the disease segmentation 
technique used in this study was reliable volumes of pleural 
disease and not necessarily volumes of only mesothelioma 
tumor. To calculate lung volume and pleural disease volume 
for each patient scan, a pixel-counting technique was used.22
As an independent validation of the lung segmentation 
method, lung segmentations were performed on a separate set of 
44 CT scans from 22 patients with MPM (one baseline and one 
follow-up scan per patient). Automated lung segmentation was 
performed for each patient, and an attending radiologist (who 
was blinded to the computer results) contoured the aerated lung 
on three axial sections for the diseased (ipsilateral) hemithorax 
and healthy (contralateral) hemithorax (patients had unilateral 
disease). The area enclosed by both sets of contours was cal-
culated, and the section-by-section areas were compared using 
Pearson’s correlation coefficient and Bland–Altman analysis.23
Lung volumes were used as a response assessment 
metric by normalizing the ipsilateral lung volume by the 
contralateral lung volume for each patient scan. Although 
it is customary for CT scans to be acquired during patient 
breath-hold at full inspiration, it is possible that differences in 
patient respiratory phase between scan time points still exist. 
In patients with unilateral disease, the healthy (contralateral) 
lung can be used to normalize the volume of aerated lung 
in the diseased (ipsilateral) hemithorax, thereby controlling 
for any potential differences in inspiration. This normalized 
volume V
norm
 was calculated as follows:
 
V t
V t
V tnorm
ipsilateral
contralateral
( )=
( )
( )
.
 
(1)
TABLE 1.  Description of the Patient Cohort Used in This Study
Sex Known asbestos exposure
 Male n = 50 Yes n = 55
 Female n = 11 No n = 6
Age at diagnosis Chest pain
 Median 66 years Yes n = 38
 Range 42–80 years No n = 23
Chemotherapy Shortness of breath
 Carboplatin/Pemetrexed n = 6 Yes n = 50
 Cisplatin/Pemetrexed n = 31 No n = 11
 Cisplatin/Gemcitabine n = 24 ECOG performance status
Histology 0 n = 31
 Epithelioid n = 43 1 n = 26
 Sarcomatoid n = 5 2 n = 4
 Biphasic n = 13 Talc pleurodesis
T Stage Yes n = 27
 T1 n = 13 No n = 34
 T2 n = 16 Weight
 T3 n = 20 Median 75 kg
 T4 n = 12 Range 52–121 kg
N Stage Height
 N0 n = 17 Median 171 cm
 N1 n = 2 Range 155–188 cm
 N2 n = 32 Smoking status
 N3 n = 10 Never n = 27
M Stage Past n = 29
 M0 n = 55 Present n = 5
 M1 n = 6 Pleurectomy/decortication
IMIG Stage Yes n = 0
 I n = 9 No n = 61
 II n = 2
 III n = 29
 IV n = 21
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Data Analysis
The different tumor response assessment methods in 
this study (linear-thickness measurements, disease volumes, 
and normalized lung volumes) were compared using rank 
 correlation statistics. An R2 value is reported for the fit between 
changes in linear thickness from baseline and changes in dis-
ease volume from baseline for a spherical geometry model 
(the geometry implicit in the derivation of the RECIST clas-
sification criteria). For a sphere with diameter d that changes 
by an amount Δd, the relative volume change is given by the 
following equation: 
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To compare the prognostic performance of the different 
response assessment methods, the univariate significance of 
all three metrics was assessed using Cox proportional hazards 
(PH) models with time-varying covariates.24–26 Furthermore, 
survival models were built using each response assessment 
method, and the clinical covariates from the final multivari-
ate prognostic model obtained by Labby et al.21: Eastern 
Cooperative Oncology Group performance status discretized 
as level 0 versus levels 1 or 2, disease histology discretized 
as epithelioid versus other, and presence of dyspnea. Survival 
was defined as the duration from baseline imaging to either 
patient death or censoring (some patients in the cohort remain 
living).
All three response assessment methods were allowed to 
change over time and were modeled using scaled logarithmic 
transforms of relative changes from baseline, known as the 
specific growth rate (SGR).8 The definition of the SGR metric 
is as follows: 
 
SGR t
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where m(t) denotes the measurement (linear thickness, 
disease volume, or normalized lung volume) at an arbitrary 
time point and t
0
 indicates the time of baseline scanning (times 
in this study were all modeled as fractional years). The clini-
cal covariates mentioned earlier were included along with (1) 
linear measurement SGR, (2) disease volume SGR, or (3) nor-
malized lung volume SGR in multivariate survival models.
The performance of the survival models was assessed 
using the Heagerty’s Cτ,27 derived from receiver operating 
characteristic analysis. Cτ is especially useful for survival 
models with time-varying covariates and is scaled from 0 to 1; 
Cτ = 0.5 would indicate no prognostic ability, and Cτ = 1.0 
would indicate perfect prognostic ability. For this study, values 
of Cτ are reported from training and testing on the same data set 
and leave-one-out cross-validation performance values for the 
different models. In addition, repeated random subsampling of 
the patient cohort was used to assess the difference in predic-
tive ability between the three multivariate survival models for 
the different response assessment  methods. In each of 1000 
subsample iterations, each model was trained on two-thirds of 
the patient cohort and tested on the remaining one-third of the 
patient cohort. The training set was  chosen randomly without 
replacement at each iteration, and the testing set was consid-
ered to be the remaining patients who had not been selected 
for the training set at that iteration. Each model (using the lin-
ear-thickness SGR, disease volume SGR, or normalized lung 
volume SGR assessment metric) was trained on the training 
cohort then tested on the testing cohort. Therefore, for each 
subsample iteration, model performance statistics were tracked 
in a paired manner, and differences between models were 
assessed using the histogram of paired differences between 
testing cohort performance values. Models were considered 
significantly different if the 95% central confidence interval 
(CI) of subsample paired differences did not include a differ-
ence of zero. All analyses were performed using the academic 
edition of Revolution R Enterprise (version 4.3, based on R 
version 2.12; Revolution Analytics, Palo Alto, CA).28
RESULTS
Patients and Overall Survival
Median survival from pretreatment baseline imaging 
was 12.7 months (95% CI, 10.2–15.3 months; range, 1.7–60 
months). Of the 61 patients, there were 58 recorded deaths; the 
remaining three patients were censored after a median dura-
tion of 34 months. Across all patients, the mean pleural disease 
volume at baseline was 1312 ± 853 ml (range, 225–4449 ml). 
At the time of the first follow-up scan, the mean disease vol-
ume had reduced to 1232 ml, with geometric mean change 
from baseline of −11%. By the end of treatment, the geomet-
ric mean change in disease volume from baseline was −17%.
Lung Segmentation
Across all patients, the mean baseline ipsilateral lung 
volume was 1021 ± 574 ml, and the mean baseline contralateral 
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FIGURE 1.  Kaplan–Meier survival curves for patients with 
and without normalized ipsilateral lung volume increase 
 during the course of their therapy.
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lung volume was 2648 ± 639 ml. The mean normalized 
ipsilateral lung volume at baseline was 0.399 (range, 0.058–
1.262). By the first follow-up scan, the normalized ipsilateral 
lung volume had increased to 0.420, with a 5% increase in 
geometric mean from baseline. By the end of treatment, the 
normalized ipsilateral lung volume had increased a geometric 
mean of 8% from baseline. Over the course of the entire 
treatment, the distinction between normalized ipsilateral lung 
volume increase and decrease was significantly associated with 
patient survival. Figure 1 shows the Kaplan–Meier survival 
curves for the two patient groups (log-rank p = 0.0003).
The extent of manual intervention necessary in the 
 otherwise fully automated lung segmentation was minimal. 
For cases that required any intervention whatsoever (21% 
of all scans), the duration of manual intervention averaged 
approximately 1 minute. Only 1.9% of cases required 5 min-
utes or more of manual intervention. The predominant cause 
for manual editing of lung segmentations was erroneous 
inclusion of segmented bowel gas.
From the lung segmentation validation study (which did 
not allow manual intervention), there was very high agree-
ment for area measurements of per-section lung segmentations 
between the manual approach and the automated method for the 
132 axial sections evaluated. Pearson’s correlation coefficient 
was calculated as 0.973 (p < 0.0001). Using Bland–Altman 
analysis (Fig. 2), the mean bias indicated that automated lung 
area measurements were on average 1.17 cm2 larger than man-
ual measurements (or 1.1% larger given that the average sec-
tion lung area was 102.03 cm2). The 95% limits of agreement 
in the difference between manual measurements and automated 
measurements were −19.52 to 17.19 cm2, relatively small given 
the correlation and average measurement magnitude.
Linear and Volumetric 
Measurement Correlations
A plot comparing the relative change from baseline of 
linear-thickness measurements and disease volumes for the 
61 patients in this study is shown in Figure 3. Each of the 
155 points on the plot represents a single paired change from 
baseline (i.e., if a patient has a baseline CT scan and three 
follow-up scans, there will be three data points comparing 
linear measurement change from baseline with volume 
measurement change from baseline for that patient). For these 
data, Spearman’s rank correlation coefficient was estimated to 
be ρ
thickness
 = 0.676 and Pearson’s linear correlation coefficient 
was estimated to be r
thickness
 = 0.665. Both correlations are 
positive, indicating that growth in disease linear thickness 
corresponds to growth in disease volume.
The relationship expected from a spherical geometric 
model (Eq. 2) is indicated in the plot with a dashed line. The 
quality of fit of the spherical model to the data is R2 = 0.35. 
Visual inspection of the plot indicates that the data do not reli-
ably fall along the dashed line and instead seem nearly linear 
in some locations. Although there was no theoretical reason to 
believe that mesothelioma would follow a spherical geometry 
(indeed, the shortcomings of the spherical model for this dis-
ease have already been investigated),11,29 Figure 3 provides the 
first empirical evidence for the inappropriateness of the spher-
ical assumption implicit in the standard RECIST discretized 
response classification criteria for MPM.
A plot comparing the relative change from baseline of 
normalized ipsilateral lung volumes and disease volumes for 
the 61 patients in this study is shown in Figure 4. Again, each 
of the 155 points on the plot represents a single paired change 
from baseline. The nonparametric Spearman’s rank correlation 
coefficient was estimated to be ρ
lung
 = −0.687. The linear trend 
correlation from Pearson’s correlation coefficient was estimated 
to be r
lung
 = −0.494. The correlation coefficients are negative, 
indicating that for an increase in normalized lung volume, the 
disease volume decreases. Trajectories of the two measurement 
techniques for one particular patient are shown in Figure 5.
FIGURE 2.  Validation of automated lung segmentation. (A) 
Bland–Altman plot, where bias is shown with a solid black 
line and the 95% limits of agreement are shown with dashed 
black lines. (B) Direct comparison between measurements, 
with the identity line shown.
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Survival Analysis
All three response assessment methods were 
significantly associated with patient survival in univariate Cox 
PH survival models. Increases in continuous time-varying 
linear-thickness SGR measurements were associated with 
poor patient prognosis (hazard ratio [HR] = 1.53; p < 0.0001), 
as were increases in disease volume SGR (HR = 1.32; 
p = 0.0003) and decreases in normalized ipsilateral lung 
volume SGR (HR = 0.76; p = 0.003).
In multivariate Cox PH survival models including dis-
ease histology, dyspnea, and Eastern Cooperative Oncology 
Group performance status, all three response assessment 
methods remained significantly associated with patient sur-
vival. The model coefficients for the linear-thickness model, 
disease volume model, and normalized lung volume model 
are shown in Table 2. The HR estimates for the clinical covari-
ates vary among the three multivariate survival models, but 
the variability is small compared with the 95% CIs given in 
Table 2.
Model performance was quantified using the Cτ statis-
tic. The performance of the full multivariate model trained and 
tested on the same patient cohort was 0.692, 0.680, and 0.670 
for the models using linear-thickness measurements, disease 
volume measurements, and normalized lung volume measure-
ments, respectively, along with the same clinical covariates. In 
the leave-one-out cross-validation, these scores were reduced 
slightly to 0.657, 0.625, and 0.630, respectively. Finally, the 
mean random subsample performance values for the three 
models were 0.659, 0.638, and 0.628, respectively. These val-
ues are summarized in Table 3.
Paired differences in subsample testing cohort perfor-
mance values between survival models incorporating the dif-
ferent response assessment methods were used to compare the 
utility of the different response metrics. The mean difference 
in paired Cτ performance values between the linear-thick-
ness model and the disease volume model was 0.022, with a 
95% CI of −0.077 to 0.123 and was therefore not significant 
(bootstrap p = 0.30). The mean difference in paired Cτ per-
formance values between the normalized ipsilateral lung vol-
ume model and the disease volume model was −0.009, with a 
95% CI of −0.087 to 0.077, and was therefore not significant 
(bootstrap p = 0.65). The performance of the linear-thickness 
model is on average 3.4% higher than the performance of the 
disease volume model; however, considerable overlap exists 
in the  performance of the two models (the disease volume 
model outperformed the linear-thickness model for 30% of 
the  random subsample iterations). The performance of the 
FIGURE 3.  Relative change from baseline of disease  volumes 
versus relative change from baseline of linear-thickness 
measurements. The relationship expected from a spherical 
geometric model is indicated with a dashed black line.
FIGURE 4.  Relative change from baseline of disease volumes 
versus relative change from baseline of normalized ipsilateral 
lung volumes.
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normalized ipsilateral lung volume model is on average 1.4% 
lower than the performance of the disease volume model, 
and even more overlap exists between the lung and disease 
volume models than between the linear-thickness and disease 
volume models.
DISCUSSION
In a previous study,21 it was shown for the first time that 
continuous and time-varying image-based measurements of 
pleural disease volume were significantly associated with 
patient survival in mesothelioma. This study extends the 
TABLE 2.  Multivariate Cox PH Model, Including Hazard Ratios, and 95% Confidence Intervals (CI)
Variable Hazard ratio 95% CI p Value
Linear-thickness measurement model
Linear thickness (continuous, SGR) 1.47 [1.18, 1.84] 0.00053
Histology
Epithelioid 1 – –
Other 1.95 [1.05, 3.65] 0.036
Dyspnea
No 1 – –
Yes 2.46 [1.09, 5.55] 0.030
ECOG Performance Status
0 1 – –
1 or 2 1.47 [0.83, 2.61] 0.099
Disease Volume Measurement Model
Disease Volume (continuous, SGR) 1.33 [1.13, 1.58] 0.00090
Histology
Epithelioid 1 – –
Other 2.04 [1.10, 3.79] 0.023
Dyspnea
No 1 – –
Yes 2.81 [1.19, 6.61] 0.018
ECOG Performance Status
0 1 – –
1 or 2 1.54 [0.89, 2.67] 0.12
Normalized Lung Volume Measurement Model
Normalized Lung Volume (continuous, SGR) 0.76 [0.64, 0.91] 0.0033
Histology
Epithelioid 1 – –
Other 2.38 [1.30, 4.34] 0.0050
Dyspnea
No 1 – –
Yes 2.15 [0.98, 4.74] 0.056
ECOG Performance Status
0 1 – –
1 or 2 1.58 [0.92, 2.73] 0.099
All tumor response assessment metrics were modeled as continuous specific growth rate (SGR) from baseline.
TABLE 3.  Performance Value (Cτ) Summary for Multivariate Survival Models From Table 2
Full performance LOOCV performance
Mean random subsample 
performance
95% random subsample 
confidence interval
Linear thickness 0.692 0.657 0.659 [0.556, 0.760]
Disease volume 0.680 0.625 0.638 [0.526, 0.755]
Normalized lung volume 0.670 0.630 0.628 [0.510, 0.744]
Performance values are given for full models trained and tested on the complete cohort, from leave-one-out cross-validations and from repeated random subsample simulations.
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previous investigation to three tumor response assessment 
methods: linear-thickness measurements acquired using the 
modified RECIST protocol, semiautomated segmentations of 
pleural disease volume, and automated segmentations of nor-
malized ipsilateral lung volume. These three response assess-
ment methods are all significantly associated with patient 
survival, and there are no significant differences between mod-
els that incorporate the different response metrics. Practical 
differences, however, exist among the three measurement 
techniques and the resulting models.
Until recently, measurements of complete pleural dis-
ease volume for patients with MPM were time prohibitive, 
and linear-thickness measurements remain the clinical stan-
dard for response assessment. In the past few years, several 
software algorithms for the segmentation of mesothelioma on 
CT scans have been published,14,16,19 and researchers are now 
able to explore true disease volume as a response assessment 
method. The novel response assessment metric in this study 
is lung volume; lung segmentation is a comparatively easier 
computational task than pleural disease segmentation, and 
there is a reason to expect lung volumes to be generally corre-
lated anatomically to disease volumes for patients with MPM. 
Although some gross anatomic changes to the affected hemi-
thorax are possible in mesothelioma, a decrease in disease 
volume should result in a corresponding increase in the ipsi-
lateral lung volume. Normalizing the ipsilateral lung volume 
by the contralateral lung volume corrects for differences in 
respiratory phase between a patient’s CT scans, and changes 
in normalized lung volume form a useful response assessment 
metric.
The correlations among the three response assessment 
metrics reported in this study were in line with expectations. 
One would expect changes in linear thickness to be correlated 
with changes in disease volume, as was shown; however, the 
spherical geometric relationship between tumor thickness and 
tumor volume implicit in the RECIST protocol does not hold 
in mesothelioma, as evidenced in Figure 3. The correlation 
between normalized ipsilateral lung volumes and disease vol-
umes was also as expected, as decreases in disease volume 
were met by increases in normalized ipsilateral lung volume. 
An example of this correlation is shown in Figure 5, where 
changes in normalized ipsilateral lung volume and changes 
in disease volume are seen to closely mirror one another. 
Because of the high correlation among the three metrics, 
using more than one response assessment metric in the same 
Cox PH model results in at least one of the metrics becom-
ing a nonsignificant covariate (usually with a p value > 0.20). 
Therefore, no more than one response assessment method at 
a time can be an independent significant covariate for patient 
prognosis.
The fact that the survival model with linear-thickness 
measurements outperformed (although not at a significant 
level) the disease volume survival model was unexpected. 
Disease volumes are logically better able to capture changes in 
overall tumor bulk, but perhaps changes in tumor thickness are 
physiologically more predictive of eventual patient survival 
than overall volumetric changes. The two response assess-
ment methods provide different information, and although it 
was previously assumed that disease volumes should be the 
ultimate goal of any response assessment technique, it is pos-
sible that the specific type of morphological change quanti-
fied by tumor thickness measurements is more representative 
of patient benefit. Another possibility is that human observ-
ers are able to place their baseline tumor thickness measure-
ments in locations that are in some sense more relevant for 
response assessment; volume measurements capture changes 
over the total extent of disease, while tumor thickness mea-
surements only capture change in the discrete (up to six, by 
modified RECIST) locations at which baseline measurements 
were placed. Manual linear-thickness measurements are often 
placed in areas of distinct tumor presence, whereas the disease 
volume measurements may incorporate pleural fluid in some 
patients. It may be possible to improve the performance of the 
survival model using disease volume measurements if pleural 
fluid could be more reliably excluded.
Also interesting is the nearly identical performance of 
the survival models using disease volumes and normalized 
ipsilateral lung volumes. The similar performance of the two 
models reinforces the expectation that changes in (normal-
ized) lung volume and disease volume should convey roughly 
equivalent information because of the physiological corre-
lation between the two structures. The correlation between 
paired Cτ values from random subsample testing cohorts 
showed high correlation (r = 0.77) between the survival mod-
els using disease volume and normalized ipsilateral lung 
volume.
There are various advantages and disadvantages for each 
response assessment method. It was shown by Frauenfelder et 
al.14 that the interobserver variability is substantially lower for 
disease volume measurements than for linear-thickness mea-
surements, a fact that could become an important consideration 
if disease volumes were to be used clinically to assess tumor 
response. However, linear measurements require less manual 
time than semiautomated disease volume measurements, 
and existing techniques could potentially be used to partially 
automate the linear-measurement process and thereby reduce 
time and variability.30,31 Lung volume measurement is an auto-
mated process, and the only manual intervention used in this 
study was the correction of obvious segmentation errors from 
contrast artifacts and bowel gas. It is therefore reasonable to 
believe that lung volume measurements would have almost 
no interobserver variability. However, the utility of lung vol-
ume measurements for tumor response assessment is limited 
to patients with unilateral disease and those patients who do 
not have frequent changes in pleural fluid volume (such as 
with in-dwelling pleural catheters). Although unilateral dis-
ease is most common, this stipulation necessarily precludes 
lung volume–based response assessment for a small number 
of patients.
Although talc pleurodesis causes the fusion of the pleu-
ral space, there is no evidence to suggest that the procedure 
would affect the image-based lung volume measurement 
 process. Furthermore, among the patients who underwent 
talc pleurodesis, an average of 157 days elapsed between 
the  procedure and study entry. One patient underwent talc 
pleurodesis while on study, although a span of 56 days elapsed 
486 Copyright © 2013 by the International Association for the Study of Lung Cancer
Labby et al. Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013
between talc pleurodesis and the next CT scan. Although talc 
pleurodesis induces local inflammation, this effect will likely 
have more of an impact on positron emission tomography–
based measurements of metabolic activity than on CT disease 
burden or lung volume measurements.
An inherent limitation of this study is the relatively small 
number of patients evaluated. The survival models  compared 
in this study form the starting point for a validation in inde-
pendent patient cohorts and should not be taken as definitive 
response models. Although all the survival models in this 
study had statistically significant prognostic discrimination, 
absolute performance scores of approximately 0.65 are by no 
means perfect. Although the survival model from the linear-
thickness measurements outperformed the other two models 
on average, there is no statistical basis to conclude that any 
one model is better than another. It should be further cautioned 
that the survival models in this study may not be applicable to 
patients who receive biologically different treatments than the 
cytotoxic therapy used for the patient cohort in this study.
In summary, this study compared survival models using 
three different tumor response assessment methods for patients 
with MPM undergoing chemotherapeutic treatment. Models 
were fit using clinical covariates identified in a previous study 
and linear-thickness measurements, pleural disease volume 
measurements, or normalized ipsilateral lung volume mea-
surements. As a novel tumor response assessment technique, 
lung volumes exhibited the expected correlation with disease 
volumes. All three response assessment methods were signifi-
cantly associated with patient survival. The model using linear-
thickness measurements performed, on average, better than the 
other two models, though the differences were not significant.
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